Differential diagnoses of RBD.
Abstract
Rapid eye movement (REM) sleep behavior disorder (RBD) is a parasomnia exclusively occurring during REM sleep. Viewing this disorder through a neurologic lens can provide longitudinal context for patients and their treating physicians, given the well-known association of RBD with a specific group of neurodegenerative disorders: the alpha synucleinopathies. It is important to have a high degree of clinical suspicion, the ability to make an accurate diagnosis, manage the symptoms, and more importantly monitor the patient for evolution of possible underlying neurological pathology. This chapter will discuss aspects of the clinical history, physical examination, ancillary testing, and diagnostic criteria.
Keywords
- rapid eye movement (REM)
- REM sleep behavior disorder (RBD)
- Parkinson’s disease (PD)
- alpha synucleinopathies
- dementia with Lewy bodies (LBD)
1. Introduction
There are a variety of disorders that can manifest complex movements and behaviors that happen during sleep. REM behavior disorder (RBD) is one such disorder characterized by loss of physiologic REM muscle atonia and dream enactment. Motor activity consists of highly complex, vigorous or violent dream enacting behaviors that are noticed when they result in injuries of the patient or their bed partner. Some behaviors include punching, kicking, jumping out of bed, and talking. If the patient is awoken they may recall an unpleasant dream of falling, being attacked or chased by either another person or an animal. The latter are common dream contents associated with RBD.
A disorder of the elderly, RBD onset occurs between the sixth and seventh decades [1], with an estimated prevalence of between 1 and 7.7% of the population [2]. The true extent of this disorder is largely unknown [3]. The disease is male predominant [4]. Symptoms are thought to arise from underlying dysfunction of the brainstem structures that regulate REM sleep atonia, mostly located in the dorsal mesopontine tegmentum and ventromedial medulla [4]. Injury to these areas can occur in the setting of structural lesions (such as stroke or multiple sclerosis), medication side effects (seen with certain antidepressants and beta blockers), or neuronal loss from neurodegenerative disease. There is a known association between RBD and the group of neurodegenerative conditions classified as alpha synucleinopathies. RBD is considered a prodrome of these conditions and can be present years before other neurological symptoms become apparent, thus the importance of early diagnosis and subsequent monitoring [5].
2. Diagnosis
Often RBD is a missed diagnosis, likely due to under reporting. While some patients have no recollection of their nighttime behaviors, others may simply not view these are abnormal. Obtaining an accurate clinical history then depends on corroborative information gathered from the patient’s bed partner, as they may witness the dream enactment behavior. Of note, spouses may comment on the patient’s night time behaviors being out of character as compared to how they behave during the daytime. For patients who do not have a regular bed partner, questions regarding vivid dreams (specifically of being attacked or engaged in combat) and unexplained night time injuries such as falling out of bed should be explored.
Differential diagnoses for complex nocturnal behaviors can be divided into several categories (see Table 1) including: partial arousal parasomnias, nightmare disorder, sleep related respiratory disorders, sleep related movement disorders, seizure disorders, and psychiatric disease.
Partial arousal parasomnias (arising from slow wave sleep):
Obstructive sleep apnea Periodic limb movements of sleep Nocturnal frontal lobe epilepsy Nocturnal panic attacks Sleep-related groaning (Catathrenia) |
Table 1.
NREM parasomnias | RBD |
---|---|
Occur in the first part of the night | Occur in the second part of the night |
Patient is amnestic of event | Patient recalls the event |
Variable duration (minutes or longer) | Last seconds to minutes |
Patient is difficult to arouse | Patient easily arousable |
Male predominance | Male predominance |
Provoked by sleep deprivation, stress | Unprovoked |
Higher prevalence among children | Higher prevalence among older adults |
Table 2.
SWS parasomnias vs RBD.
NFLE | RBD |
---|---|
Stereotyped asymmetric hypermotor behaviors of trunk or proximal extremities | Variable dream enacting behaviors in a self-defense manner including vocalizations |
Short duration 5–60 s | Duration is seconds to 2 min |
Patient is amnestic to the event | Patient recalls the event |
Occurs from NREM stages | Occurs during REM sleep |
May have nightly clusters | Rare, sporadic events |
Age of onset first or second decade | Age of onset fifth decade |
Table 3.
Nocturnal frontal lobe epilepsy vs RBD.
Once suspicion for RBD is raised, confirmatory polysomnogram (PSG) should be pursued as this will provide a definite diagnosis. A full attended polysomnogram set up includes: abbreviated electroencephalography leads, eye movement monitoring, nasal airflow monitoring, oronasal thermistor, mental/submental EMG, snore sensor, single ECG lead, chest/abdomen respiratory effort belts, pulse oximetry, and bilateral tibialis anterior EMG monitoring. When testing for RBD additional monitoring includes surface electromyography (EMG) preferably of the upper extremities as lower extremity movements are less specific [8]. The most sensitive information is obtained from monitoring of the chin (mental/submental electrodes) and flexor digitorum superficialis. Diagnostic features on PSG include increased muscle activity on surface EMG, specifically of both the chin and upper extremities. Activity on EMG is categorized as tonic or phasic. Tonic activity lasts longer than 15 s, while phasic activity is much shorter lasting less than 5 s. Typically, tonic activity is observed in the chin, while phasic activity is observed in both the chin and upper extremity EMG. Additionally, combined chin/arm activity should be present for at least 27% of a 30 s epoch (as per the International Classification of Sleep Disorders Guidelines). This is a highly specialized test and its interpretation relies on visual quantification, therefore technical quality is of the utmost importance [9]. Performing a full 18 channel EEG montage during routine diagnostic PSG can help rule out NFLE, especially if a complex behavior is captured on the PSG study night.
Diagnostic criteria as established by the International Classification of Sleep Disorders, Third Edition include [10]:
Repeated episodes of sleep related vocalization and/or complex motor behaviors
Behaviors are documented by polysomnogram to occur during REM sleep or based on clinical history of dream enacting behavior, are presumed to occur during REM sleep
Polysomnogram demonstrates REM sleep without atonia
Disturbance is not better explained by another sleep disorder, mental disorder, medication, or substance abuse.
3. Primary rapid eye movement sleep behavior disorder (synucleinopathies)
Once diagnosed, RBD can be classified as primary (idiopathic) or secondary.
Anosmia Autonomic dysfunction Color vision deficit Cognitive impairment Excessive daytime sleepiness Psychiatric disorders Personality changes Dopamine dysfunction Excessive EMG activity |
Table 4.
Potential biomarkers of RBD.
4. Secondary rapid eye movement sleep behavior disorder (non-synucleinopathy)
Other causes of RBD include neurologic disorders stemming from structural lesions such as pontine stroke or multiple sclerosis plaques. This can also rarely occur in the setting of progressive supranuclear palsy, Alzheimer’s disease, and Huntington disease among others. RBD can coexist with narcolepsy in 50% of patients. Medications that can precipitate RBD include antidepressants such as selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclics, and monoamine oxidase inhibitors (MAOi). Some beta blockers have also been identified as culprits.
5. Treatment
Symptomatic management of RBD should be approached from multiple angles. First, maintaining a safe sleep environment for the patient by removing objects that can inflict harm or lowering the bed closer to the floor. Bed partners may also opt for sleeping in separate bed for their own safety. Co-sleeping is an important part of intimacy, however, and this can continue by advising the patient to sleep in a sleeping bag on top of the bed shared with their loved one. Bed alarms to warn loved ones about the patient exiting the bed can also be helpful in reducing night time injuries associated with RBD.
Medical management with melatonin or low dose benzodiazepines such as clonazepam has been shown to reduce the dream enacting behaviors. Benzodiazepines are thought to work by suppressing REM sleep. Theoretically, other REM suppressant medications (including SSRIs, TCAs, selective SNRIs) may also help, given their mechanism of action. However there are no trials supporting or refuting their efficacy and some may precipitate RBD as previously mentioned. These medications do, however, have lower tolerance and abuse potential than benzodiazepines. These treatments do not modify the risk of progression to PD, MSA, or LBD. Dopaminergic agents have not been shown to reduce dream enactment behaviors but may help comorbid periodic limb movements if present. In RBD cases refractory to conventional treatment, cholinesterase inhibitors such as rivastigmine (studied in one trial) and donepezil (several cases) have been noted to reduce the number of dream enactment episodes as reported by bed partners.
6. Ethical considerations
As stated previously, development of RBD can herald a diagnosis of potentially disabling neurological disorders by over a decade. While not every patient with primary RBD will go on to develop one of these conditions, we believe that patients should be informed of the association between RBD and the alpha synucleinopathies and therefore their risk of developing one of these disorders. The discussion should be geared towards ensuring periodic follow up and reducing anxiety by answering any questions the patient may have on the subject. Serial neurologic exams, either comprehensive or focused on Parkinsonian features like tremor, rigidity, and bradykinesia should be performed. This can ensure early, effective treatment of motor and other non-motor symptoms that can positively impact patients’ quality of life.
7. Conclusion
RBD is a complex night time behavior consisting of dream enactment due to the loss of physiologic REM muscle atonia. It can be classified as idiopathic, which is in many cases a non-motor symptom of the alpha synucleinopathies. This group of neurodegenerative illnesses includes Parkinson’s disease, Lewy body dementia, and multiple system atrophy. The importance of understanding REM sleep behavior disorder and its implications cannot be overstated. Clinical suspicion and appropriate history taking, supports an early diagnosis and symptomatic management. More importantly, treating physicians are able to educate and monitor patients for the development motor symptoms suggestive of neurodegenerative disease. This window of opportunity allows for enrollment in clinical trials and emerging therapies. Secondary RBD related to structural lesions or medications is important to recognize in order to discontinue the offending agent and decrease the risk of night time injury. Medical management with melatonin or clonazepam can reduce the episodes of dream enactment. Non-medical interventions such as ensuring a safe sleeping environment can help prevent injury.
Thanks
To the wonderful staff of the Neurodiagnostic Center and Sleep Laboratory at Saint Vincent Hospital in Worcester, MA for their technical expertise.
References
- 1.
Schenk CH, Hurwitz TD, Mahowald MW. Normal and abnormal REM sleep regulation: REM sleep behavior disorder: An update on a series of 96 patients and a review of the world literature. Journal of Sleep Research. 1993; 2 (4):224 - 2.
Mahlknecht P, Seppi K, Frauscher B, et al. Probable RBD and association with neurodegenerative disease markers: A population-based study. Movement Disorders. 2015; 30 (10):1417-1421. DOI: 10.1002/mds.26350 - 3.
Haba-Rubio J, Frauscher B, et al. Prevalence and determinants of rapid eye movement sleep behavior disorder in the general population. Sleep. 2018; 41 (2):1-8. DOI: 10.1093/sleep/zsx197 - 4.
Iranzo A, Santamaria J, Tolosa E. The clinical and pathophysiological relevance of REM sleep behavior disorder in neurodegenerative diseases. Sleep Medicine Reviews. 2009; 13 :385-401 - 5.
Postuma RB et al. Quantifying the risk of neurodegenerative disease in idiopathic REM sleep behavior disorder. Neurology. 2009; 72 :1296-1300 - 6.
Irfan M, Schenk C, Howell M. Non-rapid eye movement sleep and overlap parasomnias. Continuum. 2017; 23 (4):1035-1050 - 7.
Vaughn B, D’Cruz O. Parasomnias and other nocturnal events. Sleep Disorders: Continuum Lifelong Learning in Neurology. 2007; 13 (3):225-247 - 8.
Frauscher B, Iranzo A, Gaig C, et al. Normative EMG values during REM sleep for the diagnosis of REM sleep behavior disorder. Sleep. 2012; 35 (6):835-847. DOI: 10.5665/sleep.1886 - 9.
Högl B, Iranzo A. Rapid eye movement sleep behavior disorder and other rapid eye movement parasomnias. Continuum. 2017; 23 (4):1017-1034 - 10.
American Academy of Sleep Medicine. International Classification of Sleep Disorders. 3rd ed. Darien, IL: American Academy of Sleep Medicine; 2014 - 11.
Zhou J et al. Clincal biomarkers of neurodegeneration in REM sleep behavior disorder. Journal of Sleep Medicine. 2015; 12 (2):27-23